Profile change history

What changed for Orforglipron?

A deterministic history of records added to PeptideScanner and preserved profile or record revisions connected through the reviewed Orforglipron identity.

33Total events
33Record additions
0Version changes
2Cited source years

Collection chronology

Evidence added to PeptideScanner

Browse all 33 connected records →

Showing the latest 33 additions by PeptideScanner publication date; the complete connected record set remains available on the cross-source timeline. Most recent addition: November 17, 2026.

Record added

ClinicalTrials.gov record NCT05869903

PeptideScanner retained ClinicalTrials.gov record NCT05869903 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-08-14, and PeptideScanner's reviewed identity mapping was orforglipron.

PeptideScanner change date
November 16, 2026
Cited source date
August 14, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT05872620

PeptideScanner retained ClinicalTrials.gov record NCT05872620 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-09-04, and PeptideScanner's reviewed identity mapping was orforglipron.

PeptideScanner change date
November 16, 2026
Cited source date
September 4, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT05931380

PeptideScanner retained ClinicalTrials.gov record NCT05931380 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-07-20, and PeptideScanner's reviewed identity mapping was orforglipron.

PeptideScanner change date
November 16, 2026
Cited source date
July 20, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT05971940

PeptideScanner retained ClinicalTrials.gov record NCT05971940 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-09-03, and PeptideScanner's reviewed identity mapping was orforglipron.

PeptideScanner change date
November 16, 2026
Cited source date
September 3, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT06010004

PeptideScanner retained ClinicalTrials.gov record NCT06010004 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-06-30, and PeptideScanner's reviewed identity mapping was orforglipron.

PeptideScanner change date
November 16, 2026
Cited source date
June 30, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT06109311

PeptideScanner retained ClinicalTrials.gov record NCT06109311 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-10-01, and PeptideScanner's reviewed identity mapping was orforglipron.

PeptideScanner change date
November 16, 2026
Cited source date
October 1, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT06186622

PeptideScanner retained ClinicalTrials.gov record NCT06186622 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-05-22, and PeptideScanner's reviewed identity mapping was orforglipron.

PeptideScanner change date
November 16, 2026
Cited source date
May 22, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT06192108

PeptideScanner retained ClinicalTrials.gov record NCT06192108 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-10-16, and PeptideScanner's reviewed identity mapping was orforglipron.

PeptideScanner change date
November 16, 2026
Cited source date
October 16, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT06370728

PeptideScanner retained ClinicalTrials.gov record NCT06370728 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-07-17, and PeptideScanner's reviewed identity mapping was orforglipron.

PeptideScanner change date
November 16, 2026
Cited source date
July 17, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT06440980

PeptideScanner retained ClinicalTrials.gov record NCT06440980 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-07-17, and PeptideScanner's reviewed identity mapping was orforglipron.

PeptideScanner change date
November 16, 2026
Cited source date
July 17, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT06649045

PeptideScanner retained ClinicalTrials.gov record NCT06649045 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-09-14, and PeptideScanner's reviewed identity mapping was orforglipron.

PeptideScanner change date
November 16, 2026
Cited source date
September 14, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT06672549

PeptideScanner retained ClinicalTrials.gov record NCT06672549 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-11-04, and PeptideScanner's reviewed identity mapping was orforglipron.

PeptideScanner change date
November 16, 2026
Cited source date
November 4, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT06672939

PeptideScanner retained ClinicalTrials.gov record NCT06672939 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-11-04, and PeptideScanner's reviewed identity mapping was orforglipron.

PeptideScanner change date
November 16, 2026
Cited source date
November 4, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT06704763

PeptideScanner retained ClinicalTrials.gov record NCT06704763 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-05-26, and PeptideScanner's reviewed identity mapping was orforglipron.

PeptideScanner change date
November 16, 2026
Cited source date
May 26, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT06972459

PeptideScanner retained ClinicalTrials.gov record NCT06972459 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-07-29, and PeptideScanner's reviewed identity mapping was orforglipron.

PeptideScanner change date
November 16, 2026
Cited source date
July 29, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT06993792

PeptideScanner retained ClinicalTrials.gov record NCT06993792 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-07-31, and PeptideScanner's reviewed identity mapping was orforglipron.

PeptideScanner change date
November 16, 2026
Cited source date
July 31, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT07153471

PeptideScanner retained ClinicalTrials.gov record NCT07153471 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-10-08, and PeptideScanner's reviewed identity mapping was orforglipron.

PeptideScanner change date
November 16, 2026
Cited source date
October 8, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT07202884

PeptideScanner retained ClinicalTrials.gov record NCT07202884 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-11-04, and PeptideScanner's reviewed identity mapping was orforglipron.

PeptideScanner change date
November 16, 2026
Cited source date
November 4, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT07223593

PeptideScanner retained ClinicalTrials.gov record NCT07223593 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-11-04, and PeptideScanner's reviewed identity mapping was orforglipron.

PeptideScanner change date
November 16, 2026
Cited source date
November 4, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT07241390

PeptideScanner retained ClinicalTrials.gov record NCT07241390 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-11-04, and PeptideScanner's reviewed identity mapping was orforglipron.

PeptideScanner change date
November 16, 2026
Cited source date
November 4, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT07613307

PeptideScanner retained ClinicalTrials.gov record NCT07613307 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-10-08, and PeptideScanner's reviewed identity mapping was orforglipron.

PeptideScanner change date
November 16, 2026
Cited source date
October 8, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT07729332

PeptideScanner retained ClinicalTrials.gov record NCT07729332 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-07-27, and PeptideScanner's reviewed identity mapping was orforglipron.

PeptideScanner change date
November 16, 2026
Cited source date
July 27, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT07739537

PeptideScanner retained ClinicalTrials.gov record NCT07739537 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-08-31, and PeptideScanner's reviewed identity mapping was orforglipron.

PeptideScanner change date
November 16, 2026
Cited source date
August 31, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT07790861

PeptideScanner retained ClinicalTrials.gov record NCT07790861 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-10-13, and PeptideScanner's reviewed identity mapping was orforglipron.

PeptideScanner change date
November 16, 2026
Cited source date
October 13, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT07794579

PeptideScanner retained ClinicalTrials.gov record NCT07794579 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-11-05, and PeptideScanner's reviewed identity mapping was orforglipron.

PeptideScanner change date
November 16, 2026
Cited source date
November 5, 2026
Evidence lane
Clinical trials
Record added

GLP-1 Receptor Agonist Orforglipron for Adults with Obesity.

PubMed lists PMID 38091541 in The New England journal of medicine as Letter, Comment, with publication-date metadata of 2023-12-14 (day precision). PeptideScanner associated the retained record with the identity slug orforglipron. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 16, 2026
Cited source date
July 3, 2025
Evidence lane
Literature metadata
Record added

GLP-1 Receptor Agonist Orforglipron for Adults with Obesity.

PubMed lists PMID 38091542 in The New England journal of medicine as Letter, Comment, with publication-date metadata of 2023-12-14 (day precision). PeptideScanner associated the retained record with the identity slug orforglipron. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 16, 2026
Cited source date
July 3, 2025
Evidence lane
Literature metadata
Record added

GLP-1 Receptor Agonist Orforglipron for Adults with Obesity. Reply.

PubMed lists PMID 38091543 in The New England journal of medicine as Letter, Comment, with publication-date metadata of 2023-12-14 (day precision). PeptideScanner associated the retained record with the identity slug orforglipron. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 16, 2026
Cited source date
July 1, 2025
Evidence lane
Literature metadata
Record added

Pharmacokinetic Bioequivalence of Orforglipron Tablets and Capsules in Healthy Participants With Obesity or Overweight.

PubMed lists PMID 41994902 in Diabetes, obesity & metabolism as Clinical Trial, Phase I, Journal Article, Multicenter Study, Randomized Controlled Trial, with publication-date metadata of 2026-04-17 (day precision). PeptideScanner associated the retained record with the identity slug orforglipron. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 16, 2026
Cited source date
November 9, 2026
Evidence lane
Literature metadata
Record added

Orforglipron Calcium.

PubMed lists PMID 42138709 in American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists as Journal Article, with publication-date metadata of 2026-07-22 (day precision). PeptideScanner associated the retained record with the identity slug orforglipron. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 16, 2026
Cited source date
July 21, 2026
Evidence lane
Literature metadata
Record added

Orforglipron (Foundayo) for adults with obesity.

PubMed lists PMID 42420063 in Trends in pharmacological sciences as Journal Article, with publication-date metadata of 2026-07-08 (day precision). PeptideScanner associated the retained record with the identity slug orforglipron. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 16, 2026
Cited source date
August 6, 2026
Evidence lane
Literature metadata
Record added

Orforglipron for Obstructive Sleep Apnea: Research Summary.

PubMed lists PMID 43002163 in JAMA as Journal Article, with publication-date metadata of 2026-11-09 (day precision). PeptideScanner associated the retained record with the identity slug orforglipron. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 16, 2026
Cited source date
November 9, 2026
Evidence lane
Literature metadata